follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Merck, AstraZeneca announce $50M license agreement

By

Back to Top Comments Email Print

Global pharmaceutical giant Merck & Co. Inc., in the Whitehouse Station section of Readington, announced Wednesday a licensing agreement with British drugmaker AstraZeneca. The latter will pay $50 million to license Phase IIa ovarian cancer drug MK-1775.

According to the announcement, Merck will be eligible to receive future payments tied to development and regulatory milestones, plus sales-related payments and tiered royalties. AstraZeneca will be responsible for all future clinical development, manufacturing and marketing.

The agreement is contingent on expiration or termination of the waiting period under the Hart Scott-Rodino Antitrust Improvement Act.

Share This Story On:

Write to the Editorial Department at editorial@njbiz.com

advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top